These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 37522686)

  • 1. The comparative efficacy and safety of biologics and small molecules for treating patients with ulcerative colitis in Portugal: a systematic literature review and network meta-analysis.
    Sanchez Gonzalez Y; Prata R; Alves D
    Eur Rev Med Pharmacol Sci; 2023 Jul; 27(14):6744-6759. PubMed ID: 37522686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis.
    Chu X; Biao Y; Liu C; Zhang Y; Liu C; Ma JZ; Guo Y; Gu Y
    BMC Gastroenterol; 2023 Oct; 23(1):346. PubMed ID: 37803294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
    Lasa JS; Olivera PA; Danese S; Peyrin-Biroulet L
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):161-170. PubMed ID: 34856198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative of the effectiveness and safety of biological agents, small molecule drugs, and microbiome therapies in ulcerative colitis: Systematic review and network meta-analysis.
    Gao J; Nie R; Chen Y; Yang W; Ren Q
    Medicine (Baltimore); 2023 Oct; 102(43):e35689. PubMed ID: 37904440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.
    Singh S; Murad MH; Fumery M; Dulai PS; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2179-2191.e6. PubMed ID: 31945470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
    Jairath V; Chan K; Lasch K; Keeping S; Agboton C; Blake A; Patel H
    Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):711-722. PubMed ID: 33599181
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.
    Welty M; Mesana L; Padhiar A; Naessens D; Diels J; van Sanden S; Pacou M
    Curr Med Res Opin; 2020 Apr; 36(4):595-606. PubMed ID: 31960724
    [No Abstract]   [Full Text] [Related]  

  • 8. An indirect comparison of efficacy including histologic assessment and safety in biologic therapy in ulcerative colitis: Systemic review and network meta-analysis.
    Chae K; Seo YS; Yu YM; Chang MJ; Choi J
    PLoS One; 2023; 18(11):e0293655. PubMed ID: 37917756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis.
    Rokkas T; Gisbert JP; Ekmektzoglou K; Dassopoulos T; Niv Y; O'Morain C
    Eur J Gastroenterol Hepatol; 2024 May; 36(5):520-533. PubMed ID: 38477863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Efficacy of Biologics and Small Molecule Therapies in Improving Patient-Reported Outcomes in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
    Shehab M; Hassan A; Alrashed F; Abbas A; Ma C; Narula N; Jairath V; Singh S; Bessissow T
    Inflamm Bowel Dis; 2024 Aug; ():. PubMed ID: 39137239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
    Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
    Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
    Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
    J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis.
    Lu X; Jarrett J; Sadler S; Tan M; Dennis J; Jairath V
    Int J Clin Pharm; 2023 Apr; 45(2):330-341. PubMed ID: 36484968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
    Singh S; Fumery M; Sandborn WJ; Murad MH
    Aliment Pharmacol Ther; 2018 Jan; 47(2):162-175. PubMed ID: 29205406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Speed of Early Symptomatic Remission With Advanced Therapies for Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
    Ahuja D; Murad MH; Ma C; Jairath V; Singh S
    Am J Gastroenterol; 2023 Sep; 118(9):1618-1625. PubMed ID: 36976548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis.
    Panaccione R; Collins EB; Melmed GY; Vermeire S; Danese S; Higgins PDR; Kwon CS; Zhou W; Ilo D; Sharma D; Sanchez Gonzalez Y; Wang ST
    Crohns Colitis 360; 2023 Apr; 5(2):otad009. PubMed ID: 36998249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
    Moćko P; Kawalec P; Pilc A
    Pharmacotherapy; 2016 Aug; 36(8):870-9. PubMed ID: 27312826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.
    Vickers AD; Ainsworth C; Mody R; Bergman A; Ling CS; Medjedovic J; Smyth M
    PLoS One; 2016; 11(10):e0165435. PubMed ID: 27776175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
    Bonovas S; Lytras T; Nikolopoulos G; Peyrin-Biroulet L; Danese S
    Aliment Pharmacol Ther; 2018 Feb; 47(4):454-465. PubMed ID: 29205421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis.
    Trigo-Vicente C; Gimeno-Ballester V; García-López S; López-Del Val A
    Int J Clin Pharm; 2018 Dec; 40(6):1411-1419. PubMed ID: 30478492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.